The AMYPAD Diagnostic and Patient Management Study (DPMS) recently hit a significant milestone: we passed the first half of the target recruitment, with 600 participants enrolled in the study (and 373 scanned) out of a planned total of 900. Moreover, this achievement was recently followed by another positive news. Indeed, October 2019 was the best month for recruitment ever, with 60 participants enrolled (the average of the previous six months was 41). This positive trend, together with the recent activation of the last site (Karolinska Institutet, Stockholm), gives hope that the enrollment will finish within the first half of 2020. Nevertheless, the main challenge for the very next future is to increase the flow of participants with subjective cognitive decline plus (146/300) and dementia (152/300), since they are below expectations and those with mild cognitive impairment have already reached the final target (302/300). The eight active sites will do their best to calibrate their recruitment strategies.

While participant recruiting is going relatively well, data analysis is in its first stages. The first data have been collected and analysis of the data acquired in the study has started. An accurate data quality check is now required before data and results can be reliably shared with the community. This necessary work, coordinated by Daniele Altomare and Loïs Gaudibert from the DPMS team in Geneva, is currently ongoing and, thanks to the development of new data entry guidelines and the active collaboration of all sites, we expect to have a clean and ready-to-use dataset in the next months.